Variable | Tracing N (%) | Crude OR (95% CI) | Adjusted OR (95% CI) | p value | |
---|---|---|---|---|---|
Not traced | Traced | ||||
Age | |||||
18–28 years | 27 (33.3) | 92 (37) | 1 | 1 | |
29–40 years | 35 (43.2) | 101 (41) | 0.84 (0.47,1.51) | 0.88 (0.49–1.60) | 0.674 |
> 40 years | 19 (23.5) | 56 (22) | 0.86 (0.44,1.70) | 0.93 (0.46–1.87) | 0.842 |
CPT | |||||
Not received | 28 (34.6) | 91 (37) | 1.09 (0.64,1.84) | 0.89 (0.51–1.56) | 0.679 |
Received | 53 (65.4) | 158 (63) | 1 | 1 | |
Tracing methods | |||||
Phone | 15 (18.5) | 95 (38) | 2.71 (1.47,5.03) | 2.97 (1.58–5.59) | 0.001* |
Field/home visit | 66 (81.5) | 154 (62) | 1 | 1 | |
Clinical stage | |||||
I/II | 24 (29.6) | 80 (32) | 1 | 1 | |
III | 33 (40.7) | 107 (43) | 0.97 (0.53,1.77) | 1.09 (0.59–2.02) | 0.793 |
IV | 24 (29.6) | 62 (25) | 0.78 (0.40,5.26) | 0.72 (0.36–1.45) | 0.364 |
Follow-up time | |||||
< 12 months | 62 (76.5) | 160 (64) | 1 | 1 | |
> 12 months | 19 (23.5) | 89 (36) | 1.82 (1.02,3.23) | 2.13 (1.17–3.88) | 0.013* |